Satish G.

Served as Product Owner and platform strategy lead for Pfizer's global Veeva Vault ecosystem — spanning CTMS, eTMF, Clinical Data Management, and Commercial operations spanning Clinical, Regulatory, and Commercial operations — managing a multi-million-dollar portfolio and a 45+ person global organization of internal leaders and strategic partners. Platform & Product Leadership Transformed a system-centric implementation model into a product- and platform-led operating model — enabling scalability, reuse, and faster time-to-value across CTMS, eTMF, and Development Cloud. Established the Enterprise Veeva Vault Center of Excellence with standardized governance, operating models, and multi-year roadmaps that improved delivery predictability and strengthened regulatory confidence. AI & Innovation Sponsored Generative AI, AI/ML, and automation initiatives targeting study start-up optimization within GxP-regulated clinical platforms — applying model validation and risk-tiering frameworks to deliver ~30% reduction in cycle times, improving data quality, and accelerating database lock and submission readiness. Directly enabling faster patient access to therapies. Compliance & Governance Maintained sustained inspection readiness across a mission-critical R&D and Commercial digital ecosystem. Drove disciplined investment prioritization and measurable ROI across an enterprise platform portfolio. Commercial & Clinical Data Management Governed enterprise clinical data management and content platforms including Veeva Vault PromoMats, Medidata, and analytics ecosystems (Power BI, Tableau, Appian) — ensuring data integrity, operational resilience, and regulatory submission readiness across global clinical programs and commercial operations. Regulatory Technology & Compliance Maintained sustained inspection readiness across a mission-critical digital ecosystems. Leadership Philosophy Platforms as products. Data as a strategic asset. AI as an embedded capability — not a pilot.

• Compressed Veeva Vault platform deployment timelines across Clinical Operations, RIM, and QMS by building a scalable product ownership and vendor governance model — improving platform health, reducing enhancement cycle times, and delivering consistent SLA performance across a global user base. • Strengthened GxP compliance and 21 CFR Part 11 readiness across Lilly’s clinical and commercial digital ecosystem by embedding AI-enhanced workflow governance controls — enabling Lilly to pass regulatory inspections with zero critical findings on managed platforms. • Accelerated clinical data quality and analytics maturity across R&D by partnering with Regulatory Affairs, Quality, and Procurement to align digital innovation with global compliance standards — reducing manual data reconciliation effort and improving downstream reporting accuracy. • Drove technology adoption and operational value realization across R&D functions by leading enterprise-wide change management and enablement programs — ensuring platform investments translated into measurable productivity gains rather than shelfware. • Elevated organizational inspection readiness by championing enterprise governance forums focused on CAPA tracking, data quality, and audit trail integrity — building a compliance culture that proactively identified and closed gaps before regulatory scrutiny. • Drove Agile product delivery and digital transformation programs across Veeva Vault and Medidata ecosystems — building governance structures that served as the precursor to Pfizer's Center of Excellence model.

• Accelerated pharma and biotech clients’ AI governance maturity by designing enterprise risk frameworks and regulatory-aligned digital transformation roadmaps — enabling clients to deploy AI/ML capabilities with confidence in GxP-regulated environments. • Reduced vendor selection cycle times and implementation risk for mid-to-large pharma organizations by leading structured platform assessments for Veeva Vault, Salesforce Commercial Cloud, and marketing automation tools — delivering business cases that secured executive buy-in and capital approval. • Built commercial and medical affairs technology roadmaps for multiple life sciences clients by translating complex business requirements into executable platform strategies — shortening time-to-value for CRM, content management, and analytics platform deployments.

* Evaluate the growth potential and evolution of disruptive technologies. * Compare successful and unsuccessful disruptive technology business ventures. * Identify current and future machine learning, deep learning (DL), and artificial intelligence applications. * Examine how using robots for automation will transform organizational operations. * Identify potential applications of blockchain technology within various industries. To be prepared for the future, you must understand the technology that will drive it. The faculty experts at the helm of the Technology Acceleration Program have scanned the horizon to evaluate how today’s emerging technologies—Non-Fungible Token (NFTs), artificial intelligence, and smart devices—could transform into the technologies of the future. You will take in a broad scope of technologies from robotic process automation to smart contracts, exploring their potential impacts on how you organize, finance, and operate your enterprise.